The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment

Qvigstad, Christian; Tait, R. C.; Rauchensteiner, Stephan; Berntorp, Erik; Moerloose, Philippe de; Schutgens, Roger E. G.; Holme, Pål André

doi:10.1097/md.0000000000012551

Cited by 13 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with any severity of hemophilia A or B, consenting to provide information to researchers compiling epidemiologic data on the link between hemophilia, hypertension, and hematuria, were included in the study. Respective national ethical committees or the institutional review boards approved the study …”

Section: Methodsmentioning

confidence: 99%

Hematuria in aging men with hemophilia: Association with factor prophylaxis

Qvigstad

Tait

Moerloose

et al. 2020

Research and Practice in Thrombosis and Haemostasis

Self Cite

View full text Add to dashboard Cite

Introduction Macroscopic hematuria is considered a significant risk factor for urologic disease, and it is highly prevalent in people with hemophilia. Aim To determine whether prophylactic factor replacement therapy is associated with reduced occurrence of macroscopic hematuria in people with hemophilia in a post hoc analysis using data from a cross‐sectional study conducted by the Age‐Related Developments and Comobordities in Hemophilia (ADVANCE) Working Group that included males with hemophilia ≥40 years of age. Methods Data from 16 contributing centers, in 13 European countries and Israel, were analyzed using logistic regression. Of 532 recruited individuals, this analysis included 370 patients with moderate or severe hemophilia who received on‐demand or prophylactic therapy. Results For patients with a history of macroscopic hematuria, we analyzed the association between prophylaxis and reoccurrence of macroscopic hematuria within the past 5 years (n = 235 patients). Frequent (≥3 times/wk) prophylaxis was negatively associated with a recent episode of macroscopic hematuria (odds ratio [OR], 0.38; 95% confidence interval [CI], 0.18‐0.76). We also analyzed whether prophylaxis corresponded to a lower lifetime number of macroscopic hematuria episodes (n = 285 patients). Frequent prophylaxis for >15 years was associated with a lower number of episodes compared to on‐demand treatment (OR, 0.29; 95% CI, 0.16‐0.54), whereas nonsteroidal anti‐inflammatory drugs (NSAIDs) and severe hemophilia were associated with a higher number. There was no association of prophylaxis <3 times/wk with hematuria. Conclusion Frequent prophylaxis was negatively associated with the number of episodes of macroscopic hematuria in people with hemophilia. Prevalence of macroscopic hematuria was higher among individuals with severe hemophilia and those regularly using NSAIDs.

show abstract

Section: Methodsmentioning

confidence: 99%

Hematuria in aging men with hemophilia: Association with factor prophylaxis

Qvigstad

Tait

Moerloose

et al. 2020

Research and Practice in Thrombosis and Haemostasis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Acute HCV infection is asymptomatic in most cases and therefore was rarely recognised in PWH during the HCV epidemic. The proportion of HCV-infected PWH in whom the infection did not progress to chronic HCV varies in different reports from 7% to 23%, [24][25][26][27][28][29][30][31] of which most estimates range between 10% and 20%. [24][25][26][27][28]31 These percentages of spontaneous clearance are slightly lower than the average 26% spontaneous clearance rate in other HCV populations.…”

Section: The Natural History Of Hcv Infection In Haemophiliamentioning

confidence: 99%

“…The proportion of HCV-infected PWH in whom the infection did not progress to chronic HCV varies in different reports from 7% to 23%, [24][25][26][27][28][29][30][31] of which most estimates range between 10% and 20%. [24][25][26][27][28]31 These percentages of spontaneous clearance are slightly lower than the average 26% spontaneous clearance rate in other HCV populations. 32 Likely, this is due to the relatively high number of HIV co-infected PWH, which is known to significantly decrease the chance of spontaneous clearance.…”

Section: The Natural History Of Hcv Infection In Haemophiliamentioning

confidence: 99%

“…24,33,34 In those in whom the HCV infection progressed to a chronic infection, the most common HCV genotypes were genotype 1 (65-70%), followed by genotype 3 and 2 with 15-20% and 10-15% respectively. [24][25][26][27]30,31 Chronic HCV infection can lead to the development of liver fibrosis and eventually cirrhosis. The 'gold standard' for diagnosis of liver fibrosis and cirrhosis is liver biopsy.…”

Section: The Natural History Of Hcv Infection In Haemophiliamentioning

confidence: 99%

See 1 more Smart Citation

Viral hepatitis in haemophilia: historical perspective and current management

et al. 2021

View full text Add to dashboard Cite

The introduction of clotting factor concentrates has substantially improved the lives of people with clotting factor deficiencies. Unfortunately, the transmission of blood-borne viral infections through these plasma-derived products led to a huge epidemic of human immunodeficiency virus and viral hepatitis in people with haemophilia (PWH). In a significant proportion of PWH exposed to these viruses, the ensuing decades-long chronic infection resulted in excess morbidity and mortality. Fortunately, developments in the safety of blood products, as well as vaccination and highly effective antiviral treatments have improved the prospects of PWH. The present article reviews the background of the viral hepatitis epidemic in PWH, the natural history of hepatitis B and C infections and their long-term management.

show abstract

“…Respective national ethical committees or the institutional review boards approved the study. [ 9 , 15 ]…”

Section: Methodsmentioning

confidence: 99%

Macroscopic hematuria as a risk factor for hypertension in ageing people with hemophilia and a family history of hypertension

Qvigstad

Sørensen²,

Tait

et al. 2020

Medicine

Self Cite

View full text Add to dashboard Cite

Ageing people with hemophilia (PWH) have a higher prevalence of hypertension than the general population. This study aimed to determine whether macroscopic hematuria was associated with hypertension in PWH in a post hoc analysis using data from a cross-sectional study conducted by the ADVANCE Working Group (the H3 study), which included PWH ≥ 40 years of age. Data from 16 contributing centers, located in 13 European countries and Israel, were analyzed using logistic regression models. Of 532 recruited PWH in the H3 study, 117 had hypertension and a positive family history of hypertension (hypertension FH+), 75 had hypertension and a negative family history of hypertension (hypertension FH−), 290 had no diagnosis of hypertension, and the remaining 50 had missing hypertension data. Logistic regressions showed that macroscopic hematuria was associated with hypertension FH+, both in the univariate (OR = 1.84 [1.17–2.90], P = .01) and in the multivariate model (OR = 1.80 [1.03–3.16], P = .04). Macroscopic hematuria was not associated with hypertension FH−. Moreover, in a multivariate logistic regression the odds of hypertension FH+ were increased with the number of macroscopic hematuria episodes. The association between macroscopic hematuria and hypertension was significant for PWH with a family history of hypertension.

show abstract

The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment

Cited by 13 publications

References 38 publications

Hematuria in aging men with hemophilia: Association with factor prophylaxis

Hematuria in aging men with hemophilia: Association with factor prophylaxis

Viral hepatitis in haemophilia: historical perspective and current management

Macroscopic hematuria as a risk factor for hypertension in ageing people with hemophilia and a family history of hypertension

Contact Info

Product

Resources

About